Teva Pharmaceutical Industries Limited
TEVA
$16.33
-$0.13-0.79%
| Weiss Ratings | TEVA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D+ | |||
| Reward Grade | E | |||
| Rating Factors | TEVA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Good | |||
| Volatility Index | Fair | |||
| Beta / Standard Deviation | TEVA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.44 | |||
| Price History | TEVA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 6.38% | |||
| 30-Day Total Return | -7.90% | |||
| 60-Day Total Return | -1.09% | |||
| 90-Day Total Return | -11.49% | |||
| Year to Date Total Return | -23.33% | |||
| 1-Year Total Return | 21.59% | |||
| 2-Year Total Return | 88.35% | |||
| 3-Year Total Return | 117.73% | |||
| 5-Year Total Return | 128.39% | |||
| 52-Week High % Change | -28.38% | |||
| 52-Week Low % Change | 30.54% | |||
| Price | TEVA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $22.80 | |||
| 52-Week Low Price | $12.51 | |||
| 52-Week Low Price (Date) | Apr 19, 2024 | |||
| 52-Week High Price (Date) | Dec 26, 2024 | |||
| Valuation | TEVA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 18.71B | |||
| Enterprise Value | 33.94B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.46 | |||
| Earnings Per Share Growth | 181.76% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 1.12 | |||
| Price/Book (Q) | 3.45 | |||
| Enterprise Value/Revenue (TTM) | 2.05 | |||
| Price | $16.33 | |||
| Enterprise Value/EBITDA (TTM) | 7.66 | |||
| Enterprise Value/EBIT | 10.06 | |||
| Market Cap Category | Large Cap | |||
| Dividends and Shares | TEVA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 1.13B | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | $0.07 | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | $0.07 | |||
| Company Info | TEVA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 972 3 914 8213 | |||
| Address | -- | |||
| Website | www.tevapharm.com | |||
| Country | Israel | |||
| Year Founded | 1901 | |||
| Profitability | TEVA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 20.39% | |||
| Profit Margin | -9.90% | |||
| Management Effectiveness | TEVA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 5.09% | |||
| Return on Equity | -- | |||
| Income Statement | TEVA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 16.54B | |||
| Total Revenue (TTM) | 16.54B | |||
| Revenue Per Share | $14.60 | |||
| Gross Profit (TTM) | 8.06B | |||
| EBITDA (TTM) | 4.43B | |||
| EBIT (TTM) | 3.37B | |||
| Net Income (TTM) | -1.64B | |||
| Net Income Avl. to Common (TTM) | -1.64B | |||
| Total Revenue Growth (Q YOY) | -5.12% | |||
| Earnings Growth (Q YOY) | -158.89% | |||
| EPS Diluted (TTM) | -1.46 | |||
| EPS Diluted Growth (Q YOY) | -147.46% | |||
| Balance Sheet | TEVA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 3.30B | |||
| Cash Per Share (Q) | $2.91 | |||
| Total Current Assets (Q) | 12.55B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 5.72B | |||
| Current Ratio (Q) | 0.981 | |||
| Book Value Per Share (Q) | $4.74 | |||
| Total Assets (Q) | 39.33B | |||
| Total Current Liabilities (Q) | 12.80B | |||
| Total Debt (Q) | 18.18B | |||
| Total Liabilities (Q) | 33.61B | |||
| Total Common Equity (Q) | 5.37B | |||
| Cash Flow | TEVA - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 792.00M | |||
| Cash from Financing (TTM) | -1.79B | |||
| Net Change in Cash (TTM) | 73.00M | |||
| Levered Free Cash Flow (TTM) | 2.61B | |||
| Cash from Operations (TTM) | 1.25B | |||
